Investment Premium

If the boom in biotech IPOs is over family offices won’t be happy


A recent surge in biotech IPOs haven’t quite met investor expectations raising some concerns about future listings in the sector from backers like family/private investment offices.  Biotech continues to be […]

This is a Premium article. Please subscribe to continue reading.

Leave a Reply

Your email address will not be published. Required fields are marked *